Eledon Pharmaceuticals, Inc. reported its first quarter 2025 operating and financial results on May 14, 2025. The company maintained a strong cash position with $124.9 million in cash, cash equivalents, and short-term investments as of March 31, 2025, and expects this to fund operations through the end of 2026.
Research and development (R&D) expenses for Q1 2025 were $13.5 million, an increase from $7.4 million in Q1 2024, reflecting continued investment in its clinical pipeline. General and administrative (G&A) expenses also increased to $4.4 million from $3.5 million in the prior-year period.
The net loss for Q1 2025 was $6.5 million, or $0.08 per basic share, a notable improvement from a net loss of $23.6 million, or $0.79 per share, in Q1 2024. This reduction was primarily driven by a $10.1 million non-cash gain from changes in the fair value of warrant liabilities, compared to a $13.3 million loss from the same in Q1 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.